Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sutter

Showing results (151-160 of 155) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 155 results.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Frontiers in Immunology|January 25, 2024
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Nature Communications|April 20, 2026
Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitisBeibei Liu, Marianne R Spalinger, Annalisa Invernizzi, et al.
Annals of Hepatology|October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabLorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Journal of Cardiac Surgery|June 12, 2021
Cardiac surgeons' concerns, perceptions, and responses during the COVID-19 pandemicJessica G Y Luc, Niv Ad, Tom C Nguyen, et al.
Pageof 16

Showing results (151-160 of 155) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 155 results.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Frontiers in Immunology|January 25, 2024
PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Nature Communications|April 20, 2026
Indirect inhibition of the NLRP3-interleukin-1β axis contributes to the efficacy of JAK1 inhibitors in experimental colitis and human ulcerative colitisBeibei Liu, Marianne R Spalinger, Annalisa Invernizzi, et al.
Annals of Hepatology|October 13, 2025
Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumabLorenz Kocheise, Jan Kempski, Yunhe Tang, et al.
Journal of Cardiac Surgery|June 12, 2021
Cardiac surgeons' concerns, perceptions, and responses during the COVID-19 pandemicJessica G Y Luc, Niv Ad, Tom C Nguyen, et al.
Pageof 16